How much funding has Corvus Pharmaceuticals raised?

Corvus Pharmaceuticals has raised $319.1M in total funding, most recently a Corporate Round.

Who are Corvus Pharmaceuticals's investors?

Corvus Pharmaceuticals's investors include OrbiMed, Rock Springs Capital, Adams Street Partners, Novo Holdings A/S, Roche.

When was Corvus Pharmaceuticals founded?

Corvus Pharmaceuticals was founded in 2014.

Where is Corvus Pharmaceuticals headquartered?

Corvus Pharmaceuticals is headquartered in Burlingame, California, United States.

What industry is Corvus Pharmaceuticals in?

Corvus Pharmaceuticals operates in Biotech, Healthcare.

How many employees does Corvus Pharmaceuticals have?

Corvus Pharmaceuticals has 11-50 employees.

Corvus Pharmaceuticals

IPO

Pioneering ITK inhibition

Public · Burlingame, United States · Founded 2014 · $319.1M raised

Biotech

Healthcare

Headquarters: Burlingame, California
Employees: 11–50
Founded: 2014
Business Model: B2B
Website: corvuspharma.com

Total Funding: $319.1M
Last Round: $150.0M Corporate RoundJan 2026
Rounds: 5
Type: Public

About

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies with the potential to significantly improve the treatment of immune diseases and cancer. The company's lead program, soquelitinib, is a first-in-class oral therapy that selectively inhibits ITK (interleukin-2-inducible T-cell kinase) to modulate and control parallel signaling pathways in the immune system. The founding team includes inventors and scientists behind Rituxan (rituximab), Imbruvica (ibrutinib), and Zelboraf (vemurafenib). ITK inhibition represents a novel approach to immune modulation that the company believes parallels the transformative impact of those landmark therapies in oncology and autoimmune disease.

Summary

Corvus Pharmaceuticals is a Biotech company based in Burlingame, United States, founded in 2014. It has raised $319.1M in total across 5 rounds, most recently a $150.0M Corporate Round round in Jan 2026. Investors include OrbiMed, Rock Springs Capital and Adams Street Partners.